Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
2don MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsJay Short - Co-Founder, CEO & ChairmanSheri Lydick - ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback